IP Verse

Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Patent No. EP3305285 (titled "Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer") was filed by Aragon Pharmaceuticals on Sep 23, 2013. The application was issued on Sep 2, 2020.

Patent Summary

A method for treating non-metastatic castration-resistant prostate cancer (NM-CRPC) in male humans comprises administering a therapeutically effective amount of the anti-androgen 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. The anti-androgen binds the androgen receptor ligand-binding domain, inhibiting nuclear translocation, DNA binding, and coactivator recruitment without agonist activity. Treatment requires maintaining castrated testosterone levels via orchiectomy or co-administration of a GnRH agonist (e.g., leuprolide, goserelin) or antagonist. The method targets high-risk NM-CRPC, including patients with a PSA doubling time $\le$10 months, to increase metastasis-free survival and achieve PSA90 at 3 or 6 months, or PSA50 at 6 months. The anti-androgen may be administered orally once, twice, or three times daily.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANDOZJun 2, 2021MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
SYNTHONJun 2, 2021HAMM&WITTKOPP PATENTANWÄLTE PARTMBB
TEVA PHARMACEUTICAL INDUSTRIES LTDJun 2, 2021D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3305285

ARAGON PHARMACEUTICALS
Application Number
EP17187458A
Filing Date
Sep 23, 2013
Status
Revoked
Aug 22, 2024
Publication Date
Sep 2, 2020
External Links
Slate, Register , Google Patents